Adverse effects of statins - mechanisms and consequences.
about
Statins for children with familial hypercholesterolemiaHerbal medicines for fatty liver diseasesChinese herbal medicines for hypertriglyceridaemiaStatins for children with familial hypercholesterolemiaChinese herbal medicines for hypercholesterolemiaHerbal medicines for fatty liver diseasesModulation of h(2)s metabolism by statins: a new aspect of cardiovascular pharmacologyMuscular effects of statins in the elderly female: a reviewA novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitroStatin-associated ocular disorders: the FDA and ADRAC data.Investigating the effects of statins on cellular lipid metabolism using a yeast expression system.Statins and New-Onset Diabetes Mellitus: LDL Receptor May Provide a Key Link.Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury networkSafety of statins: an updateStatins and myocardial remodelling: cell and molecular pathways.Molecular mechanisms underlying the effects of statins in the central nervous system.Targeting Rac1 signaling inhibits streptococcal M1 protein-induced CXC chemokine formation, neutrophil infiltration and lung injuryEffects of simvastatin and metformin on polycystic ovary syndrome after six months of treatmentExploring adverse drug events at the class level.Identification of NF-κB inhibitors in Qishenyiqi dropping pills for myocardial infarction treatment based on bioactivity-integrated UPLC-Q/TOF MS.Activation of GPR55 Receptors Exacerbates oxLDL-Induced Lipid Accumulation and Inflammatory Responses, while Reducing Cholesterol Efflux from Human Macrophages.A Mutation in Caenorhabditis elegans NDUF-7 Activates the Mitochondrial Stress Response and Prolongs Lifespan via ROS and CED-4Life with too much polyprenol: polyprenol reductase deficiency.Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis.Statins and risk of treated incident diabetes in a primary care populationSafety of statins.Effect of Statins on the Nanomechanical Properties of Supported Lipid Bilayers.Management of statin intolerancePharmacotherapy of dyslipidemias in the adult population.Poststroke fatigue: an emerging, critical issue in stroke medicine.Statins in the management of dyslipidemia associated with chronic kidney disease.Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.The controversy of a wider statin utilization: why?Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.Plant polyisoprenoids and control of cholesterol level.Learning from berberine: Treating chronic diseases through multiple targets.The adjuvant value of Herba Cistanches when used in combination with statin in murine models.Streptococcal m1 protein triggers farnesyltransferase-dependent formation of CXC chemokines in alveolar macrophages and neutrophil infiltration of the lungs.Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling.Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice.
P2860
Q24194816-AE8D69F1-0923-4628-AC3C-BBF5F61D2C24Q24200256-B4393CA4-5729-4FFB-AF68-BB8DD19B5330Q24202020-F24C1590-EF44-4C6F-A46C-960A0C450040Q24234081-CB267E75-5D91-4C34-A83C-DF3A604AAA47Q24235695-B21703F3-28B0-4580-B10F-2FBB55092D35Q24236298-14863579-1859-464B-8AF5-86253EE61B10Q27001076-F8C0B6C4-A7BA-4929-9D8D-23475BE74B1CQ27023343-D4D5350F-51DE-4171-AADD-B08032E4E5A8Q28247578-597E5CDB-3714-4729-A409-4848EFBE930BQ30943920-847F605B-689C-4C4B-B847-EF782AB03E5DQ33521217-A2052F68-BC4E-4756-8684-8757BBAD7258Q33790331-65FE34C8-6BA3-4E72-BED2-7149602B9DABQ33946592-FD3ACBA0-58F3-40FB-A064-5EAE4BB801E4Q33949312-CF9E2D6A-9A94-4353-B014-731DBDBDD27BQ34196628-F14B9018-EBD8-4F8F-AE7C-EEA56FC9181BQ34685463-237AFA4F-75E8-43B6-8FB4-45862CCAB181Q34948690-B117AD8E-5CB3-4401-98C8-B1B39FFB4966Q35497969-AEAFA589-A607-4093-AE44-AEEC222E7F02Q35559500-91F1A7C1-D3D7-4014-AFC7-846E92691430Q35595583-8689FE2A-E471-43E1-BC72-FD5F454CCD1FQ35602343-B465F1EE-8D41-46B0-8942-A16E5A4F326AQ35926396-8179E177-5EF9-4DB6-ADD1-7B1999B245FDQ36191596-4CC7262F-BFF4-4DBA-B14C-61BC5128A8C1Q36598388-4F63DC7E-CD19-404A-88EF-A2B741595F06Q36729984-E9EACFDD-D1B6-40D9-9492-C8B45732ACCAQ37095088-11FB54DE-0CA9-4138-A5E6-2EAFBAEA7D3AQ37141978-D3D0859E-BFCF-4561-A7E8-6A8DFC69582CQ37414000-744FBAF8-21CD-4E47-80A3-6A34A4458E68Q37801374-859B8307-50A3-4F5C-B12E-B9C87F37A548Q37899950-550470E5-A19C-4454-9275-37FA6F976420Q37986355-EC6C2A9B-23A4-430D-B60A-A5FCF0CE7FD5Q38076217-D5E1FB59-2785-437D-A981-DC580260829EQ38089090-6F9D84C9-0D6B-4DE5-AC01-EADF5F6B3CBBQ38109960-BE81DC05-B1EE-44DB-B08A-AD4F5935865DQ38133372-B2E0EF99-28DB-46B0-AE70-83497A604CBCQ38156718-C955DB13-BEBE-4A04-9333-7C6E3542B2FEQ41516471-BFBEF498-C353-4C5F-801F-68A789A00918Q41585009-4E15CB23-266E-426D-AD22-5A841AF98C2FQ41811577-728236D0-56AC-4C7D-AFD6-5913969DC852Q42254484-A08DD0C7-F699-4977-8DD0-2C908FBE71BA
P2860
Adverse effects of statins - mechanisms and consequences.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Adverse effects of statins - mechanisms and consequences.
@ast
Adverse effects of statins - mechanisms and consequences.
@en
Adverse effects of statins - mechanisms and consequences.
@nl
type
label
Adverse effects of statins - mechanisms and consequences.
@ast
Adverse effects of statins - mechanisms and consequences.
@en
Adverse effects of statins - mechanisms and consequences.
@nl
prefLabel
Adverse effects of statins - mechanisms and consequences.
@ast
Adverse effects of statins - mechanisms and consequences.
@en
Adverse effects of statins - mechanisms and consequences.
@nl
P2093
P1433
P1476
Adverse effects of statins - mechanisms and consequences.
@en
P2093
Anna Jamroz-Wiśniewska
Grazyna Wójcicka
Jerzy Bełtowski
P304
P356
10.2174/157488609789006949
P577
2009-09-01T00:00:00Z